Patents by Inventor Sophie PACZESNY

Sophie PACZESNY has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240353424
    Abstract: The present disclosure provides biomarker panels for evaluating subjects at risk of sinusoidal obstruction syndrome (SOS) early after hematopoietic stem cell transplantation (HSCT). In particular, the present disclosure relates to the use of ST2. L-Ficolin, and HA for prognosing, diagnosing, and/or treating SOS.
    Type: Application
    Filed: April 11, 2024
    Publication date: October 24, 2024
    Applicant: MUSC Foundation for Research Development
    Inventor: SOPHIE PACZESNY
  • Patent number: 11193945
    Abstract: Disclosed are biomarker panels for evaluating subjects at risk of sinusoidal obstruction syndrome (SOS) early after hematopoietic stem cell transplantation (HSCT). In particular, the present disclosure relates to the use of one or more of ST2, ANG2, L-Ficolin, HA, and VCAM1 for prognosing, diagnosing, and/or treating SOS.
    Type: Grant
    Filed: February 4, 2020
    Date of Patent: December 7, 2021
    Assignee: Indiana Research and Technology Corporation
    Inventor: Sophie Paczesny
  • Publication number: 20210309752
    Abstract: The present application relates to methods for targeting and/or inhibiting a tumoral microenvironment and/or tumor cells. More specifically, the present disclosure is directed to a method of targeting a tumor microenvironment of a subject, the method comprises, consists of, or consists essentially of inhibiting ST2* regulatory T cells present in the tumor microenvironment. The methods of the present disclosure further comprise blocking the IL-33/ST2 pathway.
    Type: Application
    Filed: August 2, 2019
    Publication date: October 7, 2021
    Inventor: Sophie PACZESNY
  • Publication number: 20200182886
    Abstract: Disclosed are biomarker panels for evaluating subjects at risk of sinusoidal obstruction syndrome (SOS) early after hematopoietic stem cell transplantation (HSCT). In particular, the present disclosure relates to the use of one or more of ST2, ANG2, L-Ficolin, HA, and VCAM1 for prognosing, diagnosing, and/or treating SOS.
    Type: Application
    Filed: February 4, 2020
    Publication date: June 11, 2020
    Inventor: Sophie PACZESNY
  • Patent number: 10571478
    Abstract: A four-biomarker panel for diagnosis of chronic graft-versus-host disease (cGVHD) and methods of prognosing and/or diagnosing cGVHD using the biomarker panel are disclosed.
    Type: Grant
    Filed: November 23, 2015
    Date of Patent: February 25, 2020
    Assignee: Indiana University Research and Technology Corporation
    Inventor: Sophie Paczesny
  • Publication number: 20180139937
    Abstract: Cell culture systems for producing IL-33 induced T9 cells and methods of using the IL-33 induced T9 cells (T9IL-33 cells) in a cell therapy for increasing anti-tumoral activity following allogeneic hematopoietic cell transplantation (HCT) and/or treating graft-versus-host disease (GVHD) are disclosed herein. Further, methods of using the T9IL-33 cells, alone or in combination with allogeneic hematopoietic cell transplantation, are described herein for cancer treatment.
    Type: Application
    Filed: May 6, 2016
    Publication date: May 24, 2018
    Inventor: Sophie Paczesny
  • Publication number: 20170261518
    Abstract: A four-biomarker panel for diagnosis of chronic graft-versus-host disease (cGVHD) and methods of prognosing and/or diagnosing cGVHD using the biomarker panel are disclosed.
    Type: Application
    Filed: November 23, 2015
    Publication date: September 14, 2017
    Inventor: Sophie Paczesny
  • Publication number: 20170248612
    Abstract: Disclosed are biomarker panels for evaluating subjects at risk of sinusoidal obstruction syndrome (SOS) early after hematopoietic stem cell transplantation (HSCT). In particular, the present disclosure relates to the use of one or more of ST2, ANG2, L-Ficolin, HA, and VCAM1 for prognosing, diagnosing, and/or treating SOS.
    Type: Application
    Filed: October 26, 2015
    Publication date: August 31, 2017
    Inventor: Sophie PACZESNY